

药学干预在降低药品不良反应中的应用

张军华

山东省滨州市药品不良反应监测中心 山东 滨州 256600

【摘要】目的: 浅析在降低药品不良反应发生率中应用药学干预措施的效果。方法: 本次研究样本共计选入 520 例, 是 2021 年 1 月-2022 年 9 月收治的患者, 其中 260 例患者 2021 年期间入院, 定义为对照组, 此时未实施药学干预措施; 2022 年开始实施药学干预, 期间入院的 260 例患者定义为实验组, 比较各组药品不良反应情况。**结果:** 实验组药品不良反应率为 6.54%, 明显低于对照组的 18.46%, 统计学意义成立 ($P < 0.05$)。在不良反应原因方法, 实验组用药禁忌占比 0.77%、用药方法有误占比 1.54%、联合用药占比 1.15%、用药剂量有误占比 2.69%, 分别低于对照组的 3.46%、4.62%、3.85%、6.54%, 统计学意义成立 ($P < 0.05$)。**结论:** 药学干预措施应用后, 能够有效降低药品不良反应发生率, 值得大力推广应用。

【关键词】: 药学干预; 药品不良反应; ADR

Application of Pharmaceutical Intervention in Reducing Adverse Drug Reactions

Junhua Zhang

Shandong Binzhou ADR Monitoring Center Shandong Binzhou 256600

Abstract: Objective: To analyze the effect of pharmaceutical intervention in reducing the incidence of adverse drug reactions. Methods: 520 patients were selected from January 2021 to September 2022. Among them, 260 patients were admitted to the hospital during 2021, which was defined as the control group. At this time, no pharmaceutical intervention measures were taken; In 2022, pharmaceutical intervention will be implemented. During this period, 260 patients admitted to the hospital will be defined as the experimental group, and the adverse drug reactions of each group will be compared. Results: The ADR rate of the experimental group was 6.54%, which was significantly lower than that of the control group (18.46%), with a statistical significance ($P < 0.05$). In the cause and method of adverse reactions, the proportion of drug contraindications, errors in drug use, combination drug use and dosage errors in the experimental group was 0.77%, 1.54%, 1.15% and 2.69%, respectively lower than 3.46%, 4.62%, 3.85% and 6.54% in the control group, which was statistically significant ($P < 0.05$). Conclusion: The application of pharmaceutical intervention measures can effectively reduce the incidence of adverse drug reactions, which is worth promoting.

Keyword: Pharmaceutical intervention; Adverse drug reactions; ADR

1 资料和方法

1.1

| ADR | ADR | 2021 | 1 | -2022 | 9 |
|-----|-----|-------------|-----|-------------|------------|
| [1] | ADR | | | | 2021 1 |
| | | | | | 260 |
| | ADR | | | | 2022 1 - 9 |
| | | | | | 260 |
| | | 42.06± 5.17 | 128 | | 132 |
| | | 6- 74 | | 42.13± 5.58 | 125 |
| | | 135 | | | P 0.05 |

1.2

ADR^[2]

1.21 1.3 1

2

1.4

[3] SPSS22.0 %

x² P 0.05

2 结果

1.22 21

17 ADR 2

1 2 3 4

5 6 2 9

[5] 48 ADR 2

1 5 6 6 7

9 11 14

11 23 ADR

P 0.05

1

| n,% | | | | | | |
|----------------|-----|------------|-----------|------------|------------|-------------|
| | | | | | | |
| | 260 | 3 1.15 | 7 2.69 | 2 0.77 | 5 1.92 | 17 6.54 |
| | 260 | 12 4.62 | 8 3.08 | 10 3.85 | 18 6.92 | 48 18.46 |
| x ² | | | | | | 16.897 |
| P | | | | | | 0.000 |

2.2

2 0.77% ADR

9 3.46% 4 1.54% ADR

12 4.62% 3

1.15% ADR 10

3.85% 7 2.69% ADR

1.23 17 6.54% P

0.05

3 讨论

" " " " " " " " " "

" "

" " " " "

" " " " "

ADR
ADR

ADR

参考文献:

- [1] [J]. ,2021,28(16):98
- [2] [J]. ,2022,39(1):3- 3.
- [3] [J]. (),2020,17(11):74- 76.
- [4] [J]. ,2020,18(6):150- 151.
- [5] [J]. ,2022,41(5):82- 85.
- [6] [J]. ,2020,5(1):159- 161.
- [7] [J]. ,2020,11(7):59- 59.

2021
260 18.46% ADR 2022
260
6.54% ADR P 0.05
ADR
P 0.05
ADR ADR